Cargando…
Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778993/ https://www.ncbi.nlm.nih.gov/pubmed/31632472 http://dx.doi.org/10.1177/1759720X19877994 |
_version_ | 1783456867041673216 |
---|---|
author | Minisola, Salvatore Cipriani, Cristiana Grotta, Giada Della Colangelo, Luciano Occhiuto, Marco Biondi, Piergianni Sonato, Chiara Vigna, Evelina Cilli, Mirella Pepe, Jessica |
author_facet | Minisola, Salvatore Cipriani, Cristiana Grotta, Giada Della Colangelo, Luciano Occhiuto, Marco Biondi, Piergianni Sonato, Chiara Vigna, Evelina Cilli, Mirella Pepe, Jessica |
author_sort | Minisola, Salvatore |
collection | PubMed |
description | Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received additional approval for the treatment of osteoporosis in men, and for the treatment of osteoporosis associated with glucocorticoid therapy in men and women at risk of fracture. In this review, we summarize the most important data concerning PTH 1-34 therapy before 2016 in the treatment of osteoporosis, and report some outstanding results published in the last 2 years. New data on safety will also discussed, together with the state of art of nonclassical utilization. Finally, in view of the recent approval of biosimilars, possible future landscapes are discussed. |
format | Online Article Text |
id | pubmed-6778993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67789932019-10-18 Update on the safety and efficacy of teriparatide in the treatment of osteoporosis Minisola, Salvatore Cipriani, Cristiana Grotta, Giada Della Colangelo, Luciano Occhiuto, Marco Biondi, Piergianni Sonato, Chiara Vigna, Evelina Cilli, Mirella Pepe, Jessica Ther Adv Musculoskelet Dis Review Following the completion of the Fracture Prevention Trial, teriparatide was approved by the United States Food and Drug Administration and the European Medicine Agency as the first therapeutic anabolic agent for the treatment of postmenopausal women with severe osteoporosis. It subsequently received additional approval for the treatment of osteoporosis in men, and for the treatment of osteoporosis associated with glucocorticoid therapy in men and women at risk of fracture. In this review, we summarize the most important data concerning PTH 1-34 therapy before 2016 in the treatment of osteoporosis, and report some outstanding results published in the last 2 years. New data on safety will also discussed, together with the state of art of nonclassical utilization. Finally, in view of the recent approval of biosimilars, possible future landscapes are discussed. SAGE Publications 2019-10-05 /pmc/articles/PMC6778993/ /pubmed/31632472 http://dx.doi.org/10.1177/1759720X19877994 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Minisola, Salvatore Cipriani, Cristiana Grotta, Giada Della Colangelo, Luciano Occhiuto, Marco Biondi, Piergianni Sonato, Chiara Vigna, Evelina Cilli, Mirella Pepe, Jessica Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title | Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title_full | Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title_fullStr | Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title_full_unstemmed | Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title_short | Update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
title_sort | update on the safety and efficacy of teriparatide in the treatment of osteoporosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778993/ https://www.ncbi.nlm.nih.gov/pubmed/31632472 http://dx.doi.org/10.1177/1759720X19877994 |
work_keys_str_mv | AT minisolasalvatore updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT ciprianicristiana updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT grottagiadadella updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT colangeloluciano updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT occhiutomarco updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT biondipiergianni updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT sonatochiara updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT vignaevelina updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT cillimirella updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis AT pepejessica updateonthesafetyandefficacyofteriparatideinthetreatmentofosteoporosis |